WHO Technical Report Series

1025

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Fifty-fourth report

World Health Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing diseases prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaption. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. To purchase WHO publications, please contact: WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; http://www.who.int/bookorders).

WHO Technical Report Series
1025

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Fifty-fourth report

This report contains the views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

World Health Organization

WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fourth report

(WHO Technical Report Series, no. 1025)

ISBN 978-92-4-000182-4 (electronic version)
ISBN 978-92-4-000183-1 (print version)

Printed in Italy

Contents

Abbreviations vi

WHO Expert Committee on Specifications for Pharmaceutical Preparations ix

Declarations of interest xiv

PRIVATE SESSION 1

Opening 1

Election of chairpersons and rapporteurs 2

1. General policy 3

1.1. Participation in meetings of the Expert Committee on Specifications for Pharmaceutical Preparations 3

OPEN SESSION 4

Introduction and welcome 4

1.2. Process for development of WHO norms and standards 5

2. General updates and matters for information 7

2.1. Cross-cutting pharmaceuticals quality assurance issues 7

2.2. International collaboration 13

3. Quality assurance – collaboration initiatives 16

3.1. International meetings of world pharmacopoeias 16

4. Nomenclature, terminology and databases 17

4.1. International Nonproprietary Names for pharmaceutical substances 17

4.2. Quality assurance terminology 18

4.3. Guidelines and guidance texts adopted by the ECSPP 18

5. Prequalification of priority essential medicines and active pharmaceutical ingredients 19

5.1. Update on the prequalification of medicines 19

5.2. Update on the prequalification of active pharmaceutical ingredients 19

6. Quality control – prequalification and WHO monitoring projects 21

6.1. Update on the prequalification of quality control laboratories 21

7. Quality control – national laboratories 23

7.1. External Quality Assurance Assessment Scheme 23

PRIVATE SESSION 25

8. Quality control – specifications and tests 25

8.1. *The International Pharmacopoeia* 25

8.2. Procedure for the development of monographs and other texts for inclusion in *The International Pharmacopoeia* 27

8.3. General policy 28
8.4. General chapters 29
8.5. General monographs for dosage forms and associated method texts 31
8.6. Specifications and draft monographs for medicines, including paediatric and radiopharmaceutical medicines 31

9. Quality control – international reference materials 39
9.1. Update on International Chemical Reference Substances 39

10. General policy – chemistry 40
10.1. Revision of guidance on representation of graphic formulae 40

11. Quality assurance – good manufacturing practices and inspection 41
11.1. Inspection guidelines and good practices with partner organizations 41
11.2. Update on the cleaning validation 43
11.3. Update on water for injection 44
11.4. Guidance on good data and record management practices 45
11.5. Update on the development of good chromatography practices 46
11.6. Quality management system requirements for national good manufacturing practice inspectorates 47
11.7. Environmental aspects of manufacturing for the prevention of antimicrobial resistance 47
11.8. Update and recommendations from the meeting on Good Practices for Health Products Manufacture and Inspection 49

12. Quality assurance – distribution and supply chain 50
12.1. Update of the *Good storage and distribution practices* guideline 50
12.2. Shelf-life for supply and procurement of medical products 50
12.3. Update and new WHO guidance, procedures and operational documents for pharmaceutical procurement 51

13. Regulatory guidance and model schemes 53
13.1. Proposal to waive in vivo bioequivalence requirements for medicines included in the *WHO Model List of Essential Medicines* 53
13.2. WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce 56
13.3. Guideline on the implementation of quality management systems for national regulatory authorities 57
13.4. Update on good regulatory practices 58
13.5. Update on new regulatory concepts and tools 59

14. Closing remarks 61

15. Summary and recommendations 62
15.1. Guidelines and decisions adopted and recommended for use 62
15.2. Texts adopted for inclusion in *The International Pharmacopoeia* 63
15.3. Recommendations 65

Acknowledgements 68

References 83

Annex 1

Procedure for the elaboration, revision and omission of monographs and other texts for *The International Pharmacopoeia* 87

Annex 2

International Atomic Energy Agency and World Health Organization guideline on good manufacturing practices for radiopharmaceutical products 93

Annex 3

Production of water for injection by means other than distillation 109

Annex 4

Good chromatography practices 115

Annex 5

Quality management system requirements for national inspectorates 129

Annex 6

Points to consider for manufacturers and inspectors: environmental aspects of manufacturing for the prevention of antimicrobial resistance 143

Annex 7

Good storage and distribution practices for medical products 157

Annex 8

Points to consider for setting the remaining shelf-life of medical products upon delivery 189

Annex 9

World Health Organization/United Nations Population Fund Prequalification Programme guidance for contraceptive devices: male latex condoms, female condoms and intrauterine devices 201

Annex 10

World Health Organization/United Nations Population Fund technical specifications for male latex condoms 221

Annex 11

World Health Organization/United Nations Population Fund specifications for plain lubricants 253

Annex 12

WHO "Biowaiver List": proposal to waive in vivo bioequivalence requirements for *WHO Model List of Essential Medicines* immediate-release, solid oral dosage forms 267

Annex 13

WHO guideline on the implementation of quality management systems for national regulatory authorities 273

Abbreviations

AMR	antimicrobial resistance
AMRH	African Medicines Regulatory Harmonization
APEC	Asia-Pacific Economic Cooperation
API	active pharmaceutical ingredient
APIMF	active pharmaceutical ingredient master file
ASEAN	Association of South-East Asian Nations
AUDA-NEPAD	African Union Development Agency-New Partnership for Africa's Development
AWaRe	access, watch and reserve
BCS	Biopharmaceutics Classification System
CRP Lite	collaborative registration procedure-Lite
EAP	WHO Expert Advisory Panel on *The International Pharmacopoeia* and Pharmaceutical Preparations
ECBS	Expert Committee on Biological Standardization
EC-EML	Expert Committee on the Selection and Use of Essential Medicines
ECSPP	Expert Committee on Specifications for Pharmaceutical Preparations
EDQM	European Directorate for the Quality of Medicines and HealthCare
EQAAS	WHO External Quality Assurance Assessment Scheme